Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.

However, this subgroup of patients showed a trend toward a shorter PFS1 compared with the counterpart free from bone metastases; the absence of statistical significance could be explained by the small sample size.

also in 53,322 other papers

In the overall population, patients with skeletal involvement at baseline had a nonsignificant trend toward worse survival compared with those who developed bone metastases at first radiological progression.

also in 5,406 other papers